Africa’s biggest drug manufacturer Aspen Pharmacare shed R18.5bn of its value on Thursday after the market took a dim view of the price it got for the sale of its infant milk business, and its reported earnings, which fell short of expectations. Aspen’s share price took its biggest intraday knock in two decades, plunging as much as 26% before recovering to close 14.8% lower at R232.06, leaving its market capitalisation at R105.9bn. The one-day decline dwarfs the market value of local drug maker Adcock Ingram, which is worth R11.1bn. If you are already a subscriber, please click on  the following link to go to the full article: Aspen sinks on sale of baby milk business If you would like to subscribe to BusinessLIVE Premium  to read the full story, please click here.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00.